> Investors > 

News Releases

Date Title  
Toggle Summary ACETO Appoints William C. Kennally, III President and CEO
PORT WASHINGTON, N.Y. , Sept. 27, 2017 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced that it has appointed William
Printer Friendly Version
Toggle Summary ACETO to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
PORT WASHINGTON, N.Y. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Sal Guccione ,
Printer Friendly Version
Toggle Summary ACETO Reports Fiscal 2017 Fourth Quarter and Full Year Results
PORT WASHINGTON, N.Y. , Aug. 24, 2017 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the
Printer Friendly Version
Toggle Summary ACETO Board of Directors Declares Quarterly Cash Dividend
PORT WASHINGTON, N.Y. , Aug. 24, 2017 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that its Board of
Printer Friendly Version
Toggle Summary ACETO Corporation Schedules Fourth Quarter & Fiscal 2017 Financial Results News Release and Conference Call Printer Friendly Version
Toggle Summary ACETO Subsidiary, Rising Pharmaceuticals, Announces Product Launches Printer Friendly Version
Toggle Summary ACETO to Present at the Singular Summer Solstice Conference Printer Friendly Version
Toggle Summary ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg Printer Friendly Version
Toggle Summary ACETO Subsidiary, Rising Pharmaceuticals, Launches Atomoxetine Capsules, 10, 18, 25, 40, 60, 80 & 100 mg Printer Friendly Version
Toggle Summary ACETO Reports Fiscal 2017 Third Quarter Results Printer Friendly Version
top